Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction

Masayoshi Suda,Karl H Paul,Utkarsh Tripathi,Tohru Minamino,Tamara Tchkonia,James L Kirkland
DOI: https://doi.org/10.1210/endrev/bnae010
2024-03-19
Endocrine Reviews
Abstract:Abstract Multiple changes occur in hormonal regulation with aging and across various endocrine organs. These changes are associated with multiple age-related disorders and diseases. A better understanding of responsible underling biological mechanisms could help in the management of multiple endocrine disorders over and above hormone replacement therapy (HRT). Cellular senescence is involved in multiple biological aging processes and pathologies common in elderly individuals. Cellular senescence, which occurs in many older individuals but also across the lifespan in association with tissue damage, acute and chronic diseases, certain drugs, and genetic syndromes, may contribute to such endocrine disorders as osteoporosis, metabolic syndrome, and type II diabetes mellitus (T2DM). Drugs that selectively induce senescent cell removal, “senolytics”, and drugs that attenuate the tissue-destructive secretory state of certain senescent cells, “senomorphics”, appear to delay the onset or alleviate multiple diseases, including but not limited to endocrine disorders such as diabetes, complications of obesity, age-related osteoporosis, and cancers as well as atherosclerosis, chronic kidney disease, neurodegenerative disorders, and many others. Over thirty clinical trials of senolytic and senomorphic agents have already been completed, are underway, or are planned for a variety of indications. Targeting senescent cells is a novel strategy that is distinct from conventional therapies such as HRT, and thus might address unmet medical needs and can potentially amplify effects of established endocrine drug regimens, perhaps allowing for dose decreases and reducing side effects.
endocrinology & metabolism
What problem does this paper attempt to address?
The paper aims to explore the role of cellular senescence and senolytics in age-related endocrine dysfunction, proposing new interventions targeting cellular senescence. Specifically, the paper focuses on how cellular senescence affects various endocrine diseases, such as diabetes and osteoporosis, and discusses the potential of delaying or alleviating these diseases by clearing senescent cells or reducing their secretion of harmful factors. The core issues of the paper are: 1. **The relationship between cellular senescence and endocrine dysfunction**: Investigating how cellular senescence leads to the decline in the function of various endocrine organs, particularly more pronounced in the elderly. 2. **Strategies for clearing senescent cells**: Introducing and evaluating "senolytics" (drugs that selectively induce the clearance of senescent cells) and "senomorphics" (drugs that reduce the secretion of harmful factors by senescent cells) in the treatment of endocrine diseases and other age-related diseases. 3. **Progress in clinical trials**: Summarizing multiple completed, ongoing, or planned clinical trials on senolytics and senomorphics to verify the efficacy and safety of these new therapies. Overall, the paper attempts to address how targeting senescent cells can improve age-related endocrine dysfunction, thereby extending healthy lifespan and enhancing the quality of life for the elderly.